News

Envisia Test May Predict Who Will Progress on Immunosuppressants

A molecular test, called the Envisia Genomic Classifier, may predict which patients with idiopathic pulmonary fibrosis (IPF) will progress on immunosuppressants, which could help doctors decide who will more likely benefit from antifibrotic therapy. The test, developed by Veracyte, can tell IPF from other types of interstitial lung…

Ofev Shows Good Safety Profile in Children With Fibrosing ILDs

The oral anti-fibrotic treatment Ofev (nintedanib) was found to be generally well-tolerated among children and adolescents with fibrosing interstitial lung diseases (ILDs) in the Phase 3 InPedILD clinical trial. “Data from the InPedILD trial demonstrate that [Ofev] has an acceptable safety and tolerability profile in children and adolescents with…

IPF Therapy PLN-74809 Showing Favorable Safety in Phase 2a Trial

Patients receiving a higher dose of PLN-74809 in the Phase 2a INTEGRIS-IPF clinical trial, which is testing the oral treatment candidate for idiopathic pulmonary fibrosis (IPF), are showing positive safety outcomes. That’s according to data from a safety review analysis conducted by the study’s data safety monitoring board (DSMB)…

PFF, Other Patient Groups, to Partner on 2nd ILD Day, Sept. 14

Focusing on raising awareness of interstitial lung diseases (ILDs), nine organizations, including the Pulmonary Fibrosis Foundation (PFF), are working together to present the second annual ILD Day, taking place Sept. 14. More than 50,000 Americans are diagnosed every year with ILD, a group of lung diseases marked by inflammation…

PF Awareness Means ‘Being Here for Each Other’ in September

From sharing stories and “going blue,” to offering yoga sessions and hosting community walks, patients and supporters are set to mark Pulmonary Fibrosis Awareness Month, held annually in September. The effort is also aimed at raising research funds to fight pulmonary fibrosis (PF), which is part of a group…

TGFBI, Protein Linked to Lung Cancer, May Be IPF Treatment Target

The levels of transforming growth factor-beta-induced protein (TGFBI), a molecule involved in lung development and cancer, are significantly increased in cellular and rodent models of idiopathic pulmonary fibrosis (IPF), a study showed. TGFBI was also found to mediate the pro-scarring effects of transforming growth factor-beta (TGF-beta) — a protein that plays…

Computer-analyzed CT Scans May Help With Early IPF Intervention

The risk of future lung-function decline and mortality in people with idiopathic pulmonary fibrosis (IPF) can be accurately predicted by a deep learning computer algorithm that evaluates CT scans, a study shows. Accurately determining the risk of progression would support early intervention before irreversible damage has occurred, the researchers…

Molecule Shows Potential to Treat PF in Surprising Manner

The small molecule TH5487 safely and effectively treated pulmonary fibrosis (PF) in a mouse model, a study reported. Although TH5487 is known to block the activity of the DNA repair enzyme OGG1, its anti-fibrotic effects occurred, in part, by reducing the production of OGG1 itself. According to researchers, these…